Good morning, HealthTech insiders. Oura filed its S-1 on Thursday, and the number that matters most is not the $1.21 billion in nine-month revenue. It's 42 billion hours. That is how much longitudinal biometric data sits in Oura's servers right now, and it's the number the company is betting will redefine it from a Finnish smart ring maker into a serious healthcare platform. At a target valuation above $16 billion, that bet is now Wall Street's problem to judge.

The same morning, Ionis Pharmaceuticals got FDA approval for the first treatment for Alexander disease, a fatal neurological disorder most doctors have never seen. ZANVASTRO won't be a blockbuster: only about 300 Americans are diagnosed. But its approval, three weeks ahead of schedule, is a reminder that healthcare's most consequential work is still happening in places that look nothing like a consumer wearable pitch deck. Today's issue is really about two different theories of what 'health technology' means, and both are winning.

CLINICAL AI

In today's Signal:

  • Oura goes public: S-1 filed September 3, $1.4B revenue, 5M paid members, 55% gross margins, target valuation above $16B on Nasdaq (ticker: OURA).

  • Ultrahuman raises $70M from Qualcomm Ventures + Labcorp to build a ring that runs software independently, not just tracks sleep.

  • ZANVASTRO FDA-approved: Ionis Pharmaceuticals wins first-ever approval for Alexander disease, an ultra-rare fatal neurological disorder, priced at $285,000/dose, three weeks ahead of deadline.

  • PatientIQ $30M Series C: 870 health systems, 70M+ patient-reported outcomes collected, the quiet infrastructure of value-based care

  • Quick hits: NHS scribe errors reach national UK media day 5, Mimrylo approved for rare blood cancer, Roivant's LISRAYA clears for dermatomyositis, smart ring IPO race takes shape

LATEST DEVELOPMENTS

CONSUMER HEALTH
1. Oura filed its S-1. The real asset isn't the ring, it's 42 billion hours of your health data.

The signal: Oura Health filed its S-1 with the SEC on September 3, targeting a Nasdaq listing under the ticker OURA, with lead underwriters Goldman Sachs, Morgan Stanley, and J.P. Morgan. Bloomberg reports the offering could raise as much as $3 billion at a valuation above $16 billion.

The details:

  • Revenue reached $1.21 billion for the nine months ended June 30, 2026, up 74% year-on-year. Full fiscal 2025 revenue was $907.9 million, up 123% from fiscal 2024. Nine-month gross margins hit 55%, and net income was $60.8 million, a sharp improvement from $1.6 million a year earlier. The headline net loss of $924.3 million reflects a deemed dividend accounting entry on preferred stock, not operating losses.

  • Oura has 5.0 million paid members as of June 30, 2026, each wearing the ring a median of 23 hours per day. The S-1 disclosed a Simple Agreement for Future Equity held by Eli Lilly, which converts to common stock at listing. 72% of members are women; 37% have household income below $100,000. CEO is Tom Hale, formerly president of Momentive.

  • The company has accumulated 42 billion hours of biometric data, described as 'one of the largest longitudinal biometric datasets in consumer health.' The S-1 discloses Oura's AI stack depends on OpenAI, Anthropic, and Google. The company holds over 1,140 patents, an active ITC enforcement moat that has blocked rivals including Ultrahuman and RingConn from the US market.

Why it matters: Consumer wearables have spent five years trying to convince insurers and health systems they belong in clinical care. Oura's IPO is the first real test of whether public markets agree. At $16B+, investors are pricing in the healthcare platform story, not just the hardware margins, and that's a very different bet than valuing a ring company.

MEDICAL DEVICES
2. Ultrahuman raised $70M from Qualcomm to build a ring that runs its own software, not just reads your sleep.

Source: TechCrunch, September 3, 2026

The signal: Bengaluru-based Ultrahuman raised $70 million (led by Qualcomm Ventures, with Labcorp, Alpha Wave, Blume, and Nexus) at a $365 million valuation, about three times its 2023 valuation. Founder and CEO Mohit Kumar says the goal is to turn the ring into an on-body computer, not just a sensor.

The details:

  • The round includes $65M in primary equity and $5M in debt. Qualcomm is co-developing a custom ring chipset that would run AI algorithms on-device rather than offloading to a phone or cloud. Planned use cases include game controller, AI assistant interface, and health-responsive hardware. Some capabilities arrive on existing Ring Air and Ring Pro via software update by end of September.

  • Labcorp's participation is the strategically interesting part. Ultrahuman is exploring whether wearable blood-flow signals combined with Labcorp blood-test data could identify cardiovascular, fertility, and aging-related risks. Annual revenue run rate is $140 million, up ~45% year-on-year. Target is $200 million by January 2027.

  • Ultrahuman was banned from US sales for much of the past year after an ITC patent dispute with Oura. US demand is running 18-20x available supply. Kumar expects to restore prior volume next quarter and triple it over four quarters. The company may not be profitable in 2026 after heavy spending on physical retail, clinical studies, and brand. framework prioritizes continuous remote sensor data to replace intermittent site visits with automated endpoint verification.

Why it matters: Labcorp investing here is not a wellness play. It's a data-access bet, the idea that continuous biometric sensing on the finger, combined with periodic lab data, might identify things neither can find alone. If that thesis gets clinical validation, the smart ring category stops being a consumer device and starts being diagnostic infrastructure.

REGULATION
3. The FDA just approved the first treatment for a disease so rare, half its US patients haven't been found yet.

The signal: The FDA approved ZANVASTRO from Ionis Pharmaceuticals (led by CEO Brett Monia) on September 4, three weeks ahead of the anticipated decision date, as the first and only disease-modifying treatment for Alexander disease, a fatal progressive neurological disorder caused by GFAP gene mutations.

The details:

  • Alexander disease affects an estimated one in 1 to 3 million people worldwide, roughly 300 Americans total. About half have been identified through medical claims; the rest haven't. It typically begins in infancy or childhood and is almost always fatal. ZANVASTRO is administered as a quarterly intrathecal injection and received a broad label covering both children and adults.

  • Ionis priced the drug at $285,000 per dose. Expected peak sales are above $100 million, but reaching that level will take time because patient identification is the real bottleneck. The company launched the Ionis Every Step support program to reduce out-of-pocket costs for commercially insured patients. Approval was based on a controlled integrated trial combining first-in-human dose-finding and a pivotal component.

  • Chief Development Officer Holly Kordasiewicz confirmed safety was consistent across pediatric and adult patients. Reimbursement flows through medical benefits under a buy-and-bill model. Approximately 150 US treatment centers can administer intrathecal therapy.

Why it matters: Three hundred patients. One treatment. Approved. The economic model for ultra-rare disease drugs is genuinely different from mainstream pharma, you price high, find patients first, and build the infrastructure to reach them. ZANVASTRO's approval is a template for antisense-based neurological therapies, and Ionis has a pipeline of them. Watch how quickly payers decide $285K per dose is justifiable for a disease that kills children.

QUICK HITS

💰 FOLLOW THE MONEY

  • The deals: Ultrahuman raised $70M (Qualcomm Ventures + Labcorp lead), valued at $365M. PatientIQ closed $30M Series C led by Hughes & Company, with Health Enterprise Partners and August Capital returning, 870 health systems, 70M+ patient outcomes collected across 20 specialties. Takeda/Protagonist's Mimrylo (rusfertide) won FDA approval for polycythemia vera, a rare blood cancer, a $300M licensing deal from 2024 that just delivered its regulatory return.

  • The pattern: This week's money split cleanly between two bets. Consumer health hardware (Ultrahuman's $70M, Oura's $16B+ IPO target) is betting that enough biometric data, plus the right diagnostic partnerships, eventually becomes clinical infrastructure. The PatientIQ and Mimrylo stories are betting the opposite, that outcomes measurement and validated therapeutics, not sensors, are where real healthcare value gets created. Both can be right. What they can't both be is the same kind of business.

🩺 THE CLINICIAN’S SIGNAL

  • On Oura's S-1 and wearable health data: 42 billion hours of passive biometric data is not the same as clinical evidence. Before ordering fewer diagnostic tests because a patient's Oura score looks good, I'd need prospective validation data in sick populations, not just healthy subscribers. Oura's S-1 doesn't include any. That's the gap between 'the most interesting health dataset in consumer tech' and 'something I can act on.'

  • On ZANVASTRO and ultra-rare disease approvals: The patient identification problem is the real clinical challenge here, not treatment delivery. Half the ~300 estimated US patients with Alexander disease haven't been found yet. For clinicians who do recognize it, the availability of a first-line disease-modifying therapy changes the calculus on genetic workup, you now have a reason to look harder, because there's something to offer if you find it.

  • On Ultrahuman + Labcorp's pairing: Combining longitudinal wearable signals with periodic blood data is a genuinely interesting clinical research question. But the pipeline from 'interesting signal' to 'diagnostic test' runs through study design, validation cohorts, and regulatory clearance. That's a five-to-seven year road, not a product update. Labcorp's bet here is a research investment, not a clinical deployment.

🛠️ Trending HealthTech AI Tools & Startups

  • Bayesian Health (bayesianhealth.com): FDA-cleared continuous sepsis monitoring AI, led by Dr. Suchi Saria. Now with CMS NTAP reimbursement at $61.84/case effective October 1. Cleveland Clinic data: 46% more sepsis cases found, 7x earlier warnings.

  • ChatGPT for Healthcare (OpenAI): Epic EHR integration launched September 1. Read-only, 325M patient records, BAA required. 99.1% physician safety rating from internal evaluation. GDPR compliance in Europe: not yet established.

  • Heartvue.ai (heartvue.ai): FDA-cleared (510k K260811) cardiac MRI AI platform with PCCP, allowing algorithm updates without new FDA submission. Founded by Dr. Jeffrey Dendy at Vanderbilt. Now in commercial rollout to US hospitals.

  • PatientIQ (patientiq.io): Patient-reported outcomes intelligence, freshly funded at $30M Series C. 70M+ outcomes across 870 health systems, 50+ EHR integrations, national clinical registries (AAOS, AANS, STS).

  • Oura Health (ouraring.com): Led by CEO Tom Hale. Filing for Nasdaq IPO (OURA) at $16B+ target. $1.4B trailing revenue, 5M subscribers, 42B hours biometric data, Eli Lilly SAFE. Goldman Sachs, Morgan Stanley, J.P. Morgan underwriting.

  • Ultrahuman (ultrahuman.com): Led by founder and CEO Mohit Kumar. $70M raised, $365M valuation, $140M ARR. Qualcomm silicon-powered ring + Labcorp clinical research partnership.

  • PatientIQ (patientiq.io): $30M Series C (Hughes & Company lead). 870 healthcare organizations, 17M patients, 70M outcomes. Expanding into real-world evidence for medical devices and a direct-to-patient marketplace.

  • Ionis Pharmaceuticals (ionispharma.com): CEO Brett Monia. ZANVASTRO FDA-approved September 4, $285K/dose, first disease-modifying therapy for Alexander disease. Antisense pipeline for neurological disorders. Nordisk & AWS: Partnered to deploy agentic AI frameworks across multi-target drug discovery pipelines.

📣 Highlights: Events, Lists & Deep Dives

That's it for today!

Two companies raised money this week with the same pitch: a tiny computer you wear on your finger will eventually become clinical infrastructure. One of them filed an S-1 to prove it to Wall Street. The other got Qualcomm and Labcorp to bet it first. The FDA, meanwhile, approved a drug for 300 patients. That's the thing about healthcare: the loudest bets and the quietest work keep happening at the same time. Both matter.

Before you go, was today’s Signal worth your time? Let us know. Your feedback helps us keep improving what we send you.

How did we do today?

See you on Monday,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.

Until tomorrow,
The HealthTech Signal